Short Interest in Addex Therapeutics Ltd (NASDAQ:ADXN) Decreases By 32.3%

Addex Therapeutics Ltd (NASDAQ:ADXNGet Free Report) was the recipient of a significant decrease in short interest during the month of April. As of April 30th, there was short interest totalling 14,700 shares, a decrease of 32.3% from the April 15th total of 21,700 shares. Based on an average daily trading volume, of 19,500 shares, the days-to-cover ratio is presently 0.8 days. Currently, 1.9% of the company’s stock are short sold.

Addex Therapeutics Stock Down 0.1 %

NASDAQ:ADXN traded down $0.01 during trading hours on Monday, reaching $9.33. 2,336 shares of the company’s stock were exchanged, compared to its average volume of 18,122. The company has a 50-day moving average of $14.31 and a 200 day moving average of $9.84. Addex Therapeutics has a 1-year low of $5.00 and a 1-year high of $27.90.

Addex Therapeutics (NASDAQ:ADXNGet Free Report) last posted its quarterly earnings results on Thursday, April 18th. The company reported ($4.06) EPS for the quarter. The business had revenue of $0.21 million during the quarter. Addex Therapeutics had a negative net margin of 644.66% and a negative return on equity of 277.56%. Sell-side analysts predict that Addex Therapeutics will post -11.8 EPS for the current year.

Hedge Funds Weigh In On Addex Therapeutics

A hedge fund recently raised its stake in Addex Therapeutics stock. Armistice Capital LLC raised its stake in Addex Therapeutics Ltd (NASDAQ:ADXNFree Report) by 103.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 537,000 shares of the company’s stock after buying an additional 273,000 shares during the period. Armistice Capital LLC owned approximately 65.33% of Addex Therapeutics worth $206,000 at the end of the most recent reporting period. 16.14% of the stock is currently owned by institutional investors and hedge funds.

About Addex Therapeutics

(Get Free Report)

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.

Read More

Receive News & Ratings for Addex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addex Therapeutics and related companies with's FREE daily email newsletter.